Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Research output: Contribution to journalJournal articleResearchpeer-review

Ingrid Marie Holst Olsen, Jens B Sørensen, Birgitte Federspiel, Andreas Kjaer, Carsten P Hansen, Ulrich Knigge, Seppo W Langer

Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
Original languageEnglish
JournalScientific World Journal
Pages (from-to)170496
Number of pages4
Publication statusPublished - 2012

ID: 48498667